Femtech: Medical devices that target women specifically. It includes products such as fertility solutions, period-tracking apps, nursing care, women’s sexual wellness, and reproductive system health care.
It is all about medtech strategy. Innumerable billion-dollar investments from U.S. government financing of the Precision Medicine program, notable product launches, and significant clinical data is the much-to-admire status of the diagnostics industry.
Maria Sainz is a former division president of Guidant/Boston Scientific, the former president and CEO of Cardiokinetix, and serves on four boards. She is is no stranger to taking risks in her career.
It is the dream of every medical device company. Re-invent a commodity product by neatly addressing all the customer’s unmet needs that have evolved over the years.
In the second installment in a series on women in medtech published in MDDI, we focus on Luann Pendy and some of the impressive programs enacted at Medtronic to promote diversity and leadership by women. They are:
In a Boston Globe article, June 13, 2017, titled; Promotion of health care execs could lift GE’s efforts in life sciences and health data, Rob Weisman, the healthcare business writer for the Boston Globe reviewed GE’s new leadership team.
It doesn’t get much better than this for the In Vitro Diagnostics market. There have been multiple billion dollar acquisitions in this space, game-changing products launched, and decisive data from clinical trials.
After a 30 year effort, 2016 data show a 17% reduction in hospital-acquired conditions (HACs). This is amazing progress! These data show a 2.1 million case decline in avoidable HAC in US patients and 87,000 lives saved.